NCT04408963View on ClinicalTrials.gov

A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

November 28, 2022

Study Completion Date

November 28, 2022

Conditions
HIV
Interventions
BIOLOGICAL

VRC-HIVMAB0102-00-AB

The VRC-HIVMAB0102-00-AB (CAP256V2LS) broadly neutralizing monoclonal antibody (bNAb) targets the V1V2 region of the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH